Andrew J: Other Devices for Heart Failure- Cardiac Contractility Modulation (CCM).


Substantial advances in the medical treatment of HFrEF have improved survival and cardiac function in these patients. However despite the use of optimal medical therapy (OMT) and the use of recommended devices in those in whom they are indicated, persistent symptoms limit activity and adversely affect lifestyle in a substantial number of patients. For these patients newer devices other than ICD and CRT may offer an improvement in symptoms and/or survival. The recent 2016 ESC/HFA guidelines for the management of heart failure[1] considered that most of these newer devices had insufficient clinical trial data for a formal recommendation, but in the case of one, cardiac contractility modulation (CCM) the guidelines describe CCM as being something to be considered in selected patients with HF. This is based on a demonstrated improvement in exercise tolerance (peak VO2) and quality of life (by Minnesota LWHF questionnaire, MLWHFQ) produced by CCM in an individual patient data meta-analysis of all the randomised controlled trials of CCM.[2] We review in this chapter the evidence for the use of CCM and discuss in which patients it may be considered as recommended in the recent guidelines.

Figure 1

Patients for whom CRT is indicated and those in whom CCM may be considered


Figure 2

The Optimizer™ System for Cardiac Contractility Modulation (CCM™) applies non-excitatory signals during the absolute refractory period


Is there a need for novel devices?

Approximately half of heart failure patients receiving OMT with persistent and restrictive symptoms (NHYA II-IV) have EF<35% and are candidates for ICD (Figure 1). Of these, approximately one third have LBBB or wide QRS>150 ms and are candidates for CRT.[1] However for the remaining 2/3 of subjects with heart failure and EF<35%, CRT is not indicated or even contraindicated (normal QRS duration).[1,3] In these patients, cardiac contractility modulation (CCM) may be considered as a means to offer symptomatic and functional benefit.

CCM device characteristics

CCM is a novel cardiac stimulation device that delivers two large amplitude (±7V) biphasic electrical pulses to the ventricular septum (Figure 2) for between 5 and 12 hours/day. Because the impulses are delivered 30 ms after the onset of the QRS and are of 20 ms duration, they are initiated and completed within the absolute refractory period of heart. Therefore these signals do not evoke depolarizations or alter the underlying cardiac activation sequence. They are not associated with initiation of ventricular arrhythmias. CCM elicits both acute and sustained improvements in contraction with favorable cardiac remodeling and improvement in symptoms and exercise tolerance. The CCM delivery system (OPTIMIZER IV) consists of three implantable commercial leads, one in the right atrium for detecting and timing atrial activation, and two bipolar electrodes in the right ventricular septum approximately 2 cm apart for sensing ventricular depolarization and delivering the CCM impulse. Leads are connected to a subcutaneously inserted pulse generator box over the pectoral muscle on the opposite side of the chest from other implanted devices (e.g. ICD). The insertion process is similar to that of a pacemaker. Because of the large current delivered, the pulse generator battery is typically charged weekly with a specialized external conductive magnet.

Figure 3A

Acute effect of increased myocardial contractility


Figure 3B

Functional and structural reverse remodeling9


Effects of CCM on cardiac function and remodeling

Onset of the CCM signal is associated with a rapid increase in isolated myocyte muscle force occurring with the next beat (Figure 3 A).[4] Offset of the force generation is equally swift. This parallels with the observed rapid increases (within 3–5 minutes) in LV ejection fraction, dP/dt, and stroke volume that are observed in vivo.[58] These hemodynamic improvements result in long term structural adaptive remodeling of the failing ventricle (Figure 11).[8,9]

Chronic improvements in cardiac contractility and structure with CCM therapy are accompanied by reversal of the foetal gene programming that occurs with heart failure and by improvement in cardiomyocyte calcium handling. ANP and BNP levels which are elevated in heart failure, are reduced with CCM treatment. Conversely expression of the primary contractile protein, α-myosin heavy chain, which is typically depressed in chronic heart failure, is increased following chronic treatment with CCM.[10,11] Heart failure is also associated with abnormal cardiomyocyte calcium handling. In humans and animals with heart failure, SERCA2a is downregulated, with reductions in phospholamban phosphorylation, reduced ryanodine receptor expression, and an elevation in the sodium-calcium exchanger content.[10] These changes reduce depolarization-induced calcium release thereby attenuating contractility. Chronic application of CCM in heart failure restores these biochemical abnormalities towards normal, thus improving contractile efficiency of the failing myocardium. Interestingly these biochemical changes are first observed in the region where impulse delivery occurs but after a few months of treatment, the beneficial adaptation extends to remote regions of the myocardium as well.[10] Each of these benefits associated with CCM treatment (structural remodeling, reversion away from the foetal gene programming, and biochemical restoration of cardiomyocyte calcium handling drives an improvement in cardiac function. Collectively they are likely responsible for the observed improvement in contractile efficiency described with CCM treatment. In humans and in animal models, CCM is associated with an increase in contractile function without an increase in myocardial oxygen consumption, thus an improvement in cardiac contractile efficiency.[12,13]

Figure 4

Individual patient data meta-analysis showing significant improvement in peak VO2 (top), 6 minute walk distance (middle) and MLWHFQ (lower).2


Clinical evaluation of CCM therapy in heart failure with reduced ejection fraction

CCM has been evaluated in more than 10 clinical trials and registries, with clinical experience in nearly 3000 patients. Enrollment has focused on patients with symptomatic (NYHA II-IV) heart failure with reduced ejection fraction (typically 35% or less) and without prolonged QRS duration. Results from the three major randomized controlled clinical trials (FIX-HF-4, FIX-HF-5, and FIX-HF-5-pilot) [7,14,15] have been compiled into a meta-analysis based on collective analysis of individual data (Figure 4).[2] Exercise tolerance (peak VO2), walking distance (6 min walk test), and quality of life (Minnesota living with heart failure questionnaire; MLWHFQ) were assessed across 641 individual subjects from the three trials. Compared to controls, those patients with CCM treatment had significantly higher pVO2 (p=0.006) with a better quality of life (MLWHFQ; p=0.0001), and a borderline significant improvement in 6MW (p=0.05). The magnitude of the overall benefit is only slightly less than what has been published with CRT. [16,17] Safety was also examined and adverse events were not significantly increased in the CCM group. In the largest randomized controlled clinical trial to date there were no differences in serious adverse event rates between OMT and OMT+CCM groups.[7]

Figure 5

CCM effects in the patients sub-group with NYHA III and LVEF ≥ 25%20


Figure 6

Larger benefits of CCM in a similar sub-group (NYHA III and LVEF ≥ 35%)18


A subgroup analysis of FIX-HF-5, planned prior to the start of the trial, suggested a greater benefit of CCM in patients with less severely reduced ejection fractions. When evaluating the 205 subjects from this trial with EF>25%, the primary endpoint (ventilatory aerobic threshold) was significantly improved by CCM, even though no effect was observed in the total cohort. Improvements in NYHA classification and MLWHFQ were observed in these patients with less severe reductions in ejection fraction (Figure 5). When limiting the analysis to those patients with EF>35%, even greater improvements in peak VO2 and MLWHF were observed (Figure 6).[18] A more recent study has also demonstrated a greater benefit of CCM in patients with moderate vs. severe reductions in EF in terms of all-cause mortality and heart failure hospitalizations.[19] These finding support an ongoing controlled randomized clinical trial of CCM+OMT vs. OMT alone in patients with moderately reduced EF (25–45%).[20] They have also prompted the Task Force that developed the 2016 ESC Guidelines for Diagnosis and Treatment of Acute and Chronic Heart Failure to comment on CCM. Although a specific guideline recommendation was not made, the guideline document indicates that in contrast to other novel devices being considered for heart failure, “CCM may be considered in selected patients with HF [heart failure]”.[1]

Long term survival analysis

Mortality has not been a primary outcome measure in any of the randomized clinical trials of CCM. However several recent publications document single and multisite experience with patients who have had chronically implanted CCM devices.

Figure 7

Reports on long term survival (or composite endpoint) with CCM compared to non-randomised matched registry derived data19,23,24


Figure 8

A composite view of several long term survival reports.[27]


Schau et al. were first to examine mortality in 54 consecutive patients with NYHA class III-IV heart failure and average EF of 23±6%. Subjects were followed for nearly 3 years and all-cause mortality was compared with mortality in a cohort with similar acuity of disease as predicted by the Seattle Heart Failure Model (SHFM).[22] At the end of 33 months, there was no difference in mortality between the CCM treated group and the SHFM prediction indicating lack of adverse effect of CCM on long-term mortality. Kuschyk and colleagues[23] published long-term follow up in 81 consecutive patients with CCM implantation at a single site. Most patients were NHYA class III and average EF was 23±8%. Survival at 1 and 3 years was better than predicted by the MAGGIC score long term mortality data. Even when correcting for the more frequent use of ICDs in the CCM cohort, mortality rates were no worse than predicted by MAGGIC. A third study was conducted across two sites in Germany by Kloppe et al.[24] who followed 68 consecutive patients implanted with CCM. Patients had NYHA class II or III symptoms and EF of 26±6%. Long term mortality was assessed and compared with that predicted by SHFM. Follow up at 1, 2 and 5 years demonstrated a survival with CCM better than predicted by SHFM at each time point. In a recent study with the longest follow-up, Liu et al.[19] examined mortality in 41 consecutively implanted (CCM) patients from a single practice. They compared mortality, hospitalization, and the composite outcome with a contemporaneous control group from a registry of patients in the same practice. Controls were matched for age, gender, EF, and etiology of heart failure. Baseline EF was 27±7% and similar between groups. Outcomes were measured over 5 years (Figure 7) and revealed a significant reduction in mortality, hospitalization, and the composite outcome at all time points measured. When patients were stratified according to ejection fraction, the improvement in survival and heart failure hospitalizations was augmented in patients with EF between 25–45% compared to matched controls, but no longer was a difference seen between CCM vs. controls for EF<25%. In a recently presented study that has not yet been published, Abraham and colleagues determined 3.4 year mortality rates among patients who were implanted with a CCM device as part of their participation in FIX-HF-5. Survival curves were compared to the most contemporary comparator group; namely, patients participating in the PARADIGM-HF study comparing the combination drug Entresto with Lisinopril. [25] Although statistical comparison was not possible between Entresto and CCM, in each group, age, gender, BMI, blood pressure, etiology of HF, and LVEF were similar. The PARADIGM-HF Enalapril group had the highest mortality rate at the 3.5 year study follow up time point, and the FIX-HF-5 subgroup (EF≥25%) had the lowest. Mortality in the PARADIGM-HF entresto cohort was similar to that in the FIX-HF-5 total group.[26] Collectively (see Figure 8), these survival studies provide strong support for conducting a prospective randomized controlled survival outcome study of CCM in patients without QRS widening and with moderate reductions in EF.


In summary, CCM is an established treatment in the management of moderate to severely symptomatic heart failure with reduced EF and normal QRS duration. CCM impulse delivery is associated with acute improvements in cardiac contractility. Chronic changes include reversion from fetal to adult gene expression profiles in the heart, improved calcium handling, restorative ventricular remodeling, and improved cardiac function. These changes are responsible for an improvement in efficiency whereby contractility increases without a corresponding increase in oxygen consumption. Randomized controlled clinical trials and their meta-analysis demonstrate improvements in quality of life, exercise capacity, and symptoms of CHF. Multiple provocative retrospective analyses suggest that CCM is associated with a reduction in mortality (especially in those with EF>25%) vs. comparable subjects with heart failure treated by OMT. CCM appears to be most efficacious in that relatively large segment of the heart failure population who have moderate to severe symptoms despite optimal medical therapy, but who do not have prolonged QRS duration or LBBB.

Declaration of Interest

The author declares no conflicts of interest.


The authors have abided by requirements for ethical publishing in biomedical journals.[28]



Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; May20pii: ehw12827206819


Giallauria F, Vigorito C, Piepoli MF, Stewart Coats AJ Effects of cardiac contractility modulation by non-excitatory electrical stimulation on exercise capacity and quality of life: An individual patient’s data meta-analysis of randomized controlled trials. Int J Cardiol 2014; Aug11752352–7 10.1016/j.ijcard.2014.06.005


Shenkman HJ, Pampati V, Khandelwal AK, McKinnon J et al Congestive heart failure and QRS duration: establishing prognosis study. Chest 2002; 122: 528–34


Burkhoff D, Shemer I, Felzen B, Shimizu J et al Electric currents applied during the refractory period can modulate cardiac contractility in vitro and in vivo. Heart failure reviews 2001; 6: 27–34


Lawo T, Borggrefe M, Butter C, Hindricks G et al Electrical signals applied during the absolute refractory period: an investigational treatment for advanced heart failure in patients with normal QRS duration. J Am Coll Cardiol 2005; 46: 2229–36


Pappone C, Rosanio S, Burkhoff D, Mika Y et al Cardiac contractility modulation by electric currents applied during the refractory period in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. The American journal of cardiology 2002; 90: 1307–13


Kadish A, Nademanee K, Volosin K, Krueger S et al A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J 2011; 161: 329–337e1–2


Morita H, Suzuki G, Haddad W, Mika Y et al Long-term effects of non-excitatory cardiac contractility modulation electric signals on the progression of heart failure in dogs. European journal of heart failure 2004; 6: 145–50


Yu CM, Chan JY, Zhang Q, Yip GW et al Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling. JACC Cardiovascular imaging 2009; 2: 1341–9


Imai M, Rastogi S, Gupta RC, Mishra S et al Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol 2007; 49: 2120–8


Butter C, Rastogi S, Minden HH, Meyhofer J et al Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure. J Am Coll Cardiol 2008; 51: 1784–9


Goliasch G, Khorsand A, Schutz M, Karanikas G et al The effect of device-based cardiac contractility modulation therapy on myocardial efficiency and oxidative metabolism in patients with heart failure. European journal of nuclear medicine and molecular imaging 2011; 39: 408–15


Butter C, Wellnhofer E, Schlegl M, Winbeck G et al Enhanced inotropic state of the failing left ventricle by cardiac contractility modulation electrical signals is not associated with increased myocardial oxygen consumption. J Card Fail 2007; 13: 137–42


Borggrefe MM, Lawo T, Butter C, Schmidinger H et al Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J 2008; 29: 1019–28


Neelagaru SB, Sanchez JE, Lau SK, Greenberg SM et al Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart rhythm: the official journal of the Heart Rhythm Society 2006; 3: 1140–7


Cazeau S, Leclercq C, Lavergne T, Walker S et al Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873–80


Abraham WT, Fisher WG, Smith AL, DeLurgio DB et al Cardiac resynchronization in chronic heart failure. NEnglJMed 2002; 346: 1845–1853


Borggrefe M, Burkhoff D Clinical effects of cardiac contractility modulation (CCM) as a treatment for chronic heart failure. European journal of heart failure 2012; 14: 703–12


Liu M, Fang F, Luo XX, Shlomo BH et al Improvement of long-term survival by cardiac contractility modulation in heart failure patients: A case-control study. International journal of cardiology 2016; 206: 122–6


Abraham WT, Nademanee K, Volosin K et al Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. J Card Fail 2011; Sep179710–7 10.1016/j.cardfail.2011.05.006


Abraham WT, Lindenfeld J, Reddy VY, Hasenfuss G et al A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with moderately reduced left ventricular ejection fraction and a narrow QRS duration: study rationale and design. J Card Fail 2015; 21: 16–23


Schau T, Seifert M, Meyhofer J, Neuss M et al Long-term outcome of cardiac contractility modulation in patients with severe congestive heart failure. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2011; 13: 1436–44


Kuschyk J, Roeger S, Schneider R, Streitner F et al Efficacy and survival in patients with cardiac contractility modulation: long-term single center experience in 81 patients. International journal of cardiology 2015; 183: 76–81


Kloppe A, Lawo T, Mijic D, Schiedat F et al Long-term survival with cardiac contractility modulation in patients with NYHA II or III. International journal of cardiology 2016;


McMurray JJ, Packer M, Desai AS, Gong J et al Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004


Abraham WT, Burkhoff D, Rousso B, Morley D et al Favorable Long-term Mortality Profile in NYHA III/IV Patients Treated with Contractility Modulation (CCM). 2016;


Shewan L.G., Coats A.J.S., Henein M. Requirements for Ethical Publishing in Biomedical Journals. International Cardiovascular Forum Journal 2015; 22


Shewan L.G., Coats A.J.S., Henein M Requirements for Ethical Publishing in Biomedical Journals. International Cardiovascular Forum Journal 2015; 2: 2

Copyright (c) 2017 Andrew Coats

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.